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ABSTRACT
Background Isolated Complex I deﬁciency is the most
common paediatric mitochondrial disease presentation,
associated with poor prognosis and high mortality.
Complex I comprises 44 structural subunits with at least
10 ancillary proteins; mutations in 29 of these have so
far been associated with mitochondrial disease but there
are limited genotype-phenotype correlations to guide
clinicians to the correct genetic diagnosis.
Methods Patients were analysed by whole-exome
sequencing, targeted capture or candidate gene
sequencing. Clinical phenotyping of affected individuals
was performed.
Results We identiﬁed a cohort of 10 patients from 8
families (7 families are of unrelated Irish ancestry) all of
whom have short stature (<9th centile) and similar facial
features including a prominent forehead, smooth
philtrum and deep-set eyes associated with a recurrent
homozygous c.64T>C, p.Trp22Arg NDUFB3 variant. Two
sibs presented with primary short stature without
obvious metabolic dysfunction. Analysis of skeletal
muscle from three patients conﬁrmed a defect in
Complex I assembly.
Conclusions Our report highlights that the long-term
prognosis related to the p.Trp22Arg NDUFB3 mutation
can be good, even for some patients presenting in acute
metabolic crisis with evidence of an isolated Complex I
deﬁciency in muscle. Recognition of the distinctive facial
features—particularly when associated with markers of
mitochondrial dysfunction and/or Irish ancestry—should
suggest screening for the p.Trp22Arg NDUFB3 mutation
to establish a genetic diagnosis, circumventing the
requirement of muscle biopsy to direct genetic
investigations.
INTRODUCTION
Mitochondrial respiratory chain disease is a signiﬁ-
cant cause of human disease with a population
prevalence of approximately 1 in 5000 in adults
and children.1 Symptoms can manifest in the neo-
natal period but onset is often later in infancy, early
childhood or even delayed to adulthood. Patients
may present with disease affecting a single organ or
have a multisystemic disorder typical of conditions
such as Leigh syndrome. Approximately 70% of
paediatric mitochondrial disease cases are caused
by nuclear gene variants, while ∼30% harbour
defects involving mitochondrially encoded
(mtDNA) genes.2 3 Conversely, mtDNA mutations
more often underlie adult mitochondrial disease
presentations.4 Beyond these prevalence statistics,
the clinical and genetic heterogeneity results in a
complex diagnostic pathway that usually relies on
biochemical analysis of a muscle biopsy to direct
genetic testing. Sanger sequencing of genes selected
and prioritised according to clinical phenotype and
biochemical results, as well as tissue biopsies, are
being replaced by next-generation sequencing
(NGS) strategies including candidate gene panels5
and whole-exome sequencing.6 7
Investigation of isolated Complex I deﬁciency is
particularly amenable to an NGS-based strategy
given the number of genes implicated in its patho-
genesis, with 44 structural subunits and at least 10
ancillary proteins required for enzyme assembly. It
is the most common paediatric mitochondrial
respiratory chain deﬁciency and mutations have
been described in at least 29 genes to date,8 almost
all being associated with a poor clinical course and
bleak prognosis.8 Here we report the clinical and
molecular genetic investigation of 10 patients from
8 unrelated families who all harbour an identical
homozygous c.64T>C, p.Trp22Arg NDUFB3
mutation, affecting a Complex I accessory subunit,
previously reported in association with severe
neurological presentations.9 10 Most of our patients
had considerably milder presentations despite har-
bouring the same variant. Recognition of mild dys-
morphic facial features common to our initial
patients prompted screening for the p.Trp22Arg
NDUFB3 variant in similar patients, leading to ﬁve
further genetic diagnoses. This report demonstrates
that the c.64T>C, p.Trp22Arg NDUFB3 mutation
can be associated with good long-term prognosis
and that recognition of a cluster of physical
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characteristics may enable rapid diagnosis of NDUFB3-related
mitochondrial disease, circumventing invasive procedures or
extensive genetic testing.
SUBJECTS AND METHODS
All patient samples were referred to the nationally commissioned
‘Highly Specialised Mitochondrial Diagnostic Laboratory’ in
Newcastle upon Tyne for investigation of a putative mitochon-
drial defect. A clinical summary for each patient is given in table
1; detailed case reports are provided as online supplementary
information. Informed parental consent was obtained.
Histochemical and biochemical analyses
Enzymatic activities of individual mitochondrial respiratory
chain complexes were determined in patient muscle biopsies as
previously described.11
Targeted next-generation sequencing
A custom 84.38 Kb Ampliseq panel was designed using the Ion
Ampliseq Designer V.2.2.1 (http://www.ampliseq.com) to target 49
genes implicated in Complex I deﬁciency (see online
supplementary table S1). To generate the barcoded Ampliseq
target library using the Ion AmpliSeq Library Kit 2.0 and Ion
Xpress Barcode Adapter 1–96 Kit, 40 ng patient DNA was used.
Libraries were quantiﬁed using an Agilent 2100 Bioanalyser and
pooled at 100 pM for emulsion PCR and enrichment using the
Ion OneTouch2 and Enrichment system. Sequencing using the Ion
PGM 200 Sequencing Kit was performed using 316 chips on an
Ion PGM Sequencer, all according to the manufacturer’s protocol.
Torrent Suite V.4.2.1 was used to align reads against the human
genome (hg19). The Variant Caller plugin was used to identify
sequence variants that were annotated using wANNOVAR.12
Whole-exome sequencing
Targeted enrichment and sequencing was performed using 3 mg
patient DNA. Enrichment was performed using the Illumina
HiSeq Sure Select All Exon v5 Enrichment Kit, and sequencing
was performed on an Illumina HiSeq 2500 sequencer, all as
directed. Sequence data were mapped with BWA software to the
human genome (hg19). Variants were called using GATK V.2.4.7
software and annotated using Ensembl V.72. Ensembl’s ‘deﬁned
consequence hierarchically’ system retained the highest impact-
ing gene variant. Filtering removed variants with ≤5× coverage,
a minor allele frequency (MAF)>1%, those predicted to be
non-functional, and those reported in dbSNP138 (unless seen in
the Human Gene Mutation Database (HGMD)) or an in-house
database (n=647 exomes).
Mutation screening, conﬁrmation and carrier testing
The c.64T>C, p.Trp22Arg NDUFB3 sequence variant was
screened and conﬁrmed using M13-tagged amplicons and
Sanger sequencing with BigDye V.3.1 kit (Life Technologies).
Capillary electrophoresis was performed using an ABI3130xl.
Familial screening for the c.64T>C, p.Trp22Arg NDUFB3
sequence variant was undertaken using parental and sibling
DNA samples where available and appropriate.
Haplotype analysis
A putative founder effect was investigated by genotyping two
proximal (D2S309 and D2S2214) and two distal (D2S116 and
D2S2309), short tandem repeat (STR) markers ﬂanking the
NDUFB3 gene. Corresponding PCR primers are listed on
Ensembl. Mapping distance was calculated using
MAP-O-MAT.13
Western blotting and blue native polyacrylamide gel
electrophoresis
Mitochondrial fractions from control and patient muscle were
prepared for western blotting and blue native polyacrylamide
gel electrophoresis (BN-PAGE) as described previously.14
Protein concentrations were determined with the Pierce
bicinchoninic acid (BCA) Protein Assay Kit. Muscle protein
extracts (100 μg) were loaded on Native PAGE 4–16% BisTris
gels, electrophoretically separated in the ﬁrst dimension before
proteins were immobilised onto a polyvinylidene ﬂuoride
(PVDF) membrane (Immobilon-P, Millipore Corporation) and
subjected to standard immunoblotting analysis of oxidative
phosphorylation (OXPHOS) complexes using primary and
horseradish peroxidise conjugated secondary antibodies as
described.14 For western blotting, equal amounts of muscle
protein (50 μg) were loaded on 12% gels and resolved by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE), followed by wet transfer to PVDF membrane and
subsequent immunodetection.
RESULTS
Clinical ﬁndings
We describe ﬁve female and ﬁve male paediatric patients, each
of whom are of short stature and share characteristic facial fea-
tures. All weighed less than the 9th centile at birth, 8/10 were
below the 2nd centile (80%). Clinical photography illustrates
the prominent forehead, poorly deﬁned philtrum and deep-set
eyes (ﬁgure 1A, B). The majority of patients presented following
a life-threatening metabolic crisis early in life followed by a
period of sustained improvement. Subsequently, their clinical
course has been largely benign but for occasional bouts of lactic
acidosis associated with minor illnesses. A previous female
sibling to patients 6 and 7 was born at term with growth restric-
tion, became unwell and died on day 2 of life with profound
lactic acidosis and multiorgan failure (no DNA was available for
analysis). Patients 8 and 9 (siblings) presented to endocrinology
for investigation of primary growth failure and were initially
suspected to have 3M syndrome. Poor linear growth was seen in
all patients, three patients have had growth hormone treatment
with variable response.
Histochemical and biochemical analyses of mitochondrial
respiratory chain enzymes
Where muscle biopsy had been performed, we identiﬁed an iso-
lated Complex I deﬁciency (table 1). No muscle biopsy was
available for patients 8 and 9 as a metabolic condition was not
suspected.
Identiﬁcation of a common underlying genetic defect
All patients in the cohort were found to harbour an identical
homozygous c.64T>C, p.Trp22Arg NDUFB3 sequence variant
(table 1). Each of the three patients analysed by targeted NGS
harboured between 54 and 57 genomic variants which were ﬁl-
tered to exclude those with a MAF >1% and variants outside
the coding region ±10 bp of the intron/exon boundaries. For
cases identiﬁed by whole exome sequencing (WES), from the
526 candidate variants compatible with autosomal recessive
inheritance only a single, homozygous variant in NDUFB3,
c.64T>C, p.Trp22Arg remained after ﬁltering. All NGS-based
strategies were conﬁrmed by conventional Sanger sequencing.
The c.64T>C (chr2(hg38):g.201078946T>C) variant is
referenced on dbSNP (rs142609245) and variant frequencies
are recorded on ESP6500 (European: 14/8586 alleles (0.16%);
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Table 1 Clinical and biochemical findings in the patient cohort
Physical appearance
Patient
(sex) Ancestry Clinical Presentation
Gestational age
and birth weight
(centile)
Age at
latest
review
Height
at review
(centile) Lactate
Short
stature
Prominent
forehead
Long/thin
philtrum
Residual CI
activity* Identified by
1 (M) English RSV+ acute respiratory collapse and hypoglycaemia aged 8 weeks
requiring intubation for 8 days. Pulmonary hypertension on
echocardiogram. Maximum-recorded lactate 14 mmol/L.
Discharged after 18 days. Normal cardiac function and
morphology at 13 months.
Term
<0.4th
9.5 years <0.4th +++ + + + 35% Targeted NGS
panel.
2 (F) Irish IUGR. Acute life-threatening event, age 20 days, required
intubation. Hypertrophic cardiomyopathy.
30weeks
2nd
6 years 2nd + + + + 33% Targeted NGS
panel.
3 (F) Irish IUGR and oligohydramnios, FTT, mild hypertrophic
cardiomyopathy.
34weeks
2nd–9th
3.5 years 0.4th–2nd ++ + + + 32% Targeted NGS
panel.
4 (F) Irish Growth restriction. Ketotic hypoglycaemia following vomiting
illness. Short stature prompted endocrinology referral. Growth
hormone therapy. MRI: high signal in periventricular white matter
and dentate nuclei.
39weeks
0.4th–2nd
8 years n.d. ++ + + + 24% Mutation screen.
5 (M) Irish IUGR. Poor feeding. Congenital hypothyroidism (strong paternal
family history). Developmental delay, growth failure, FTT, learning
difficulties. Endocrinology review for short stature.
37weeks
0.4th–2nd
10 years 0.4th + + + + 35% Mutation screen.
6 (F) Irish Oligohydramnios. IUGR. Poor feeding at birth. MRI brain and
echocardiogram normal. Age-appropriate skills. Family history of
previous neonatal death.
37weeks
<0.4th
2.5 years 2nd–9th +++ + + + 35% Mutation screen.
7 (M) Irish Sib of P6. IUGR. Normal echocardiogram and cranial ultrasound.
Normal development.
36weeks
2nd–9th
10 months 9th ++ + + + n.d. Mutation screen.
8 (M) Irish Initial poor feeding. Short stature prompted endocrinology review.
Growth hormone therapy. MRI: high signal in globus pallidus.
Echo: murmur. ECG: Wolff–Parkinson–White syndrome.
Term
0.4th–2nd
9.5 years 2nd − + + + n.d. Whole-exome
sequencing;
endocrinology.
9 (F) Irish Sib of P8. IUGR. Growth hormone therapy. Normal MRI brain,
echocardiogram and ECG.
Term
<0.4th
8 years 2nd − + + + n.d. Whole-exome
sequencing;
endocrinology.
10 (M) Irish IUGR, chronic lung disease, growth restriction and weight
faltering. Dysmorphic with partial agenesis of corpus callosum.
Acute collapse with rhinovirus bronchiolitis, severe pulmonary
hypertension at 5.5 months. Elevated lactates with intercurrent
illnesses.
31weeks
<0.4th
11 months <0.4th +++ + + + 36% Mutation screen.
*Residual Complex I activities, normalised to the activity of the matrix marker enzyme citrate synthase, are expressed as a percentage of mean control values.
FTT, failure to thrive; IUGR, intrauterine growth restriction; N.D., not determined; NGS, next-generation sequencing; RSV, respiratory syncytial virus.
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African-American: 2/4404 alleles (0.05%)) and ExAC
(Non-Finnish Europeans: 69/66 604 alleles (0.1%); African: 2/
10 390 alleles (0.02%); Latino: 1/11 568 alleles (0.01%); South
Asian: 9/16 484 alleles (0.05%)). There are no homozygous
cases recorded on either ESP650015 or ExAC16 databases.
Although the highest prevalence is recorded in European popu-
lations, the presence of the c.64T>C, p.Trp22Arg NDUFB3
variant in non-European populations suggests other independ-
ent occurrences of this pathogenic mutation.
Carrier testing
With the exception of patients 4 and 5, where familial samples
were unavailable, parental carrier testing conﬁrmed recessive
inheritance. Analysis of samples from the unaffected twin of
Figure 1 Clinical presentation associated with homozygous NDUFB3 variant (A) Clinical photographs of eight patients harbouring a homozygous
pathogenic c.64T>C, p.Trp22Arg NDUFB3 variant. Patient 1 is of English descent, whereas the remaining cases are all of Irish heritage. Patients 6/7
and 8/9 are clinically affected sibling pairs. All have characteristic physical features including a prominent forehead, smooth philtrum, deep-set eyes
and low-set ears. (B) Clinical photographs of patient 10, the youngest case within our cohort, illustrating the characteristic physical features
associated with the p.Trp22Arg NDUFB3 variant.
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patient 1 and the three unaffected siblings of patients 8 and 9
conﬁrmed the homozygous genotype segregates with a clinically
affected status.
Haplotype analysis
Analysis of the NDUFB3-ﬂanking STR markers across 0.5cM
support multiple, independent occurrences of the c.64T>C, p.
Trp22Arg variant (see online supplementary ﬁgure). Analysis of
the markers most proximal to the NDUFB3 gene (D2S309 and
D2S2309), those most likely to be in linkage disequilibrium,
shows three discrete haplotypes (1-1, 2-1 and 1-2). When
including the distal STR markers in the analysis, this increases
to seven haplotypes (a-f, plus #). There is one particularly
prevalent haplotype (‘a’) in the patient cohort that is present in
the heterozygous state in 8/10 cases and homozygous for 1/10
cases, supporting a founder allele. Additionally, the ‘b’ and ‘c’
haplotypes are present in two unrelated families. Haplotype
analysis of the two previously reported cases shows the variants
are also on the background of either the ‘a’ or ‘b’ haplotypes,
suggesting a shared founder. We infer that the ‘#’ haplotype
corresponds to the allele harbouring the truncating NDUFB3
mutation reported by Haack et al, as patient RC1 harboured a
p.Trp22Arg variant in compound heterozygosity with p.Gly70*.
Steady-state levels of respiratory chain components and
complexes
The p.Trp22Arg variant affects an evolutionary conserved
amino acid residue (ﬁgure 2A). We investigated the steady-state
protein levels of OXPHOS subunits in muscle available from
three patients harbouring a homozygous p.Trp22Arg NDUFB3
variant by SDS-PAGE and immunoblotting. The steady-state
levels of Complex I subunit proteins NDUFB8 and NDUFA9
were decreased in all three patients while levels of protein com-
ponents of Complexes II, III, IV and V were normal (ﬁgure 2B).
Analysis of the assembly of OXPHOS complex subunits into
mitochondrial respiratory chain complexes was undertaken by
BN-PAGE, showing a decrease of fully assembled Complex I in
P6, P2 and P3 muscle—correlating with the recorded biochem-
ical defect—while the assembly proﬁle of Complexes II, III, IV
and V were all normal (ﬁgure 2C). Immunoblotting with
NDUFB8 appeared to show partially assembled Complex I
intermediates of ∼650 kDa in patient muscle, consistent with
other defects involving subcomplex Iβ of the hydrophobic mem-
brane arm, of which NDUFB3 and NDUFB8 are both integral
components.17–19
DISCUSSION
Mitochondrial disease presentations are frequently heteroge-
neous, with a paucity of genotype-phenotype correlations to
direct molecular genetic testing even with a known biochemical
diagnosis. We present a cohort of 10 patients from 8 non-
consanguineous families who harbour a homozygous c.64T>C,
p.Trp22Arg NDUFB3 variant; together these patients represent
a distinct clinical presentation. The majority of patients pre-
sented with intrauterine growth restriction (IUGR) and share
characteristic facial features including a prominent forehead,
smooth philtrum, deep-set eyes and low-set ears. All patients are
short (height <9th centile) and while short stature is not
uncommon in mitochondrial disorders, dysmorphic features are
rare with the exception of PUS120 and FBXL421 mutations.
NDUFB3 encodes a structural Complex I subunit, and contrary
to reported Complex I-deﬁcient cases there were surprisingly
few persistent features of mitochondrial disease; blood lactate
levels were typically normal, although transient acidotic events
were reported following illness leading, in some cases, to hos-
pital admission before recovery. There were no seizures, ataxia
or other neurological deﬁcit noted; patients 2 and 3 had hyper-
trophic cardiomyopathy on echocardiography, but this resolved
with time. All patients are reported to be well, with good levels
of energy, attaining developmental milestones and making good
progress at school (where appropriate). Patient 10 (<1 year of
age) is much younger than the rest of our patient cohort, but is
making excellent developmental progress (see online supple-
mentary case reports).
With the exception of one patient (patient 1), all are reported
to be of Irish ancestry. Interestingly, analysis of the
NDUFB3-ﬂanking STR markers supports multiple, independent
occurrences of the c.64T>C, p.Trp22Arg variant, despite its
prevalence in the Irish population. Across the 0.5cM region ana-
lysed, there are six different p.Trp22Arg alleles; given that this
region is not a recognised recombination hot spot, it is likely
that the mutation has arisen independently and recurrently
although our data suggest a common founder for some cases
and cannot fully exclude recombination as a contributory factor.
The c.64T>C, p.Trp22Arg NDUFB3 variant is represented
on the ExAC server (0/81/121214 (homozygous/heterozygous/
alleles); MAF=6.6×10−4) and has been reported in the litera-
ture twice previously, once in compound with a nonsense muta-
tion and once as a homozygote; functional complementation
experiments conﬁrmed NDUFB3 as the causative gene defect in
both cases.9 10 The homozygous case reported by Calvo et al9
had IUGR (weight <3rd centile) and presented with hypotonia
Figure 1 Continued
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and lactic acidosis, required ventilation and died at 4 months of
age. The other reported case was born at 35 weeks gestation
with low birth weight (3rd centile), with severe lactic acidosis
and ketosis developing by day 2. Despite an initially severe pres-
entation, her symptoms ameliorated and she is reported to
remain of short stature but suffers illness-induced bouts of lactic
acidosis. An older sibling of patients 6 and 7 in our series died
on day 2 of life with profound lactic acidosis and multiorgan
failure. No underlying cause was identiﬁed but a metabolic dis-
order was suspected, prompting early metabolic investigation of
subsequent siblings.
Functional investigation of available patient muscle biopsy
revealed a marked decrease in steady state levels of Complex I
structural subunits, and although BN-PAGE analysis showed
fully assembled Complex I to be diminished, some fully
assembled Complex I remains. This is in stark contrast to many
Complex I structural subunit defects, where levels of fully
assembled Complex I are often entirely depleted,22 and could
provide an explanation for the milder clinical phenotypes
observed in our patient cohort. Nuclear modiﬁers or mtDNA
background could inﬂuence the prognosis but therapeutic inter-
vention (see online supplementary case reports) and effective
life support measures are most likely to contribute to the sur-
vival rate in our patients who presented in acute metabolic
crisis. Evidence of mitochondrial proliferation was present in
available muscle biopsy samples with elevated citrate synthase
activity and ragged-red ﬁbres indicating a cellular response to
metabolic dysfunction. Our cohort and previously reported
cases demonstrate this is a successful strategy for some but not
all. Typically, paediatric mitochondrial disease patients progres-
sively decline, with the exception of some patients with TRMU
mutations or the m.14674T>C/G mt-tRNAGlu ‘reversible cyto-
chrome c oxidase (COX) deﬁciency’ variants. We show that the
p.Trp22Arg NDUFB3 mutation can also be associated with
good long-term survival, even when some patients present in
acute metabolic crisis with an isolated Complex I deﬁciency in
muscle.
Another unique aspect of this case series involves patients 8 and
9; all other cases were referred by metabolic paediatricians but
these children were diagnosed by paediatric endocrinologists inves-
tigating primary short stature. Blood lactates were normal for both
children but patient 9 presented with Kussmaul-type respiration
aged 2 years, which could be consistent with lactic acidosis. In light
of the reported c.64T>C, p.Trp22Arg NDUFB3 cases, cardiac
Figure 2 Analysis of OXPHOS complex assembly and protein expression levels (A) Clustal Omega sequence alignment shows the evolutionary
conservation of the p.Trp22 residue (marked with asterix), based on the human sequence (amino acids 1–43). (B) Immunoblot analysis of steady
state levels of OXPHOS subunits in mitochondrial lysates isolated from control (C1, C2) and patient skeletal muscle samples (P6, P3, P2). OXPHOS
subunit-speciﬁc antibodies against the indicated proteins showed a marked decrease in Complex I subunits (NDUFB8 and NDUFA9) in patient
samples compared with controls. (C) One-dimensional blue native polyacrylamide gel electrophoresis (PAGE) (4–16% gradient) analysis showing a
defect in the assembly of Complex I in patients with the homozygous NDUFB3 variant. Individual OXPHOS complexes were detected by
immunoblotting using subunit-speciﬁc antibodies (Complex I (NDUFB8), Complex II (SDHA), Complex III (UQCRC2), Complex IV (COX1) and Complex
V (ATP5A)). The assembly of Complexes II–V was normal in all three patient samples when compared with age-matched controls. The lower panel
suggests a presence of additional, partially assembled Complex I intermediates in both control and patient samples; the upper band (indicated by *)
is likely to represent the ∼650 kDa Iβ subcomplex of the hydrophobic membrane arm while the lower band (indicated by **) represents partially
assembled intermediates which are only visible in patient samples. These were detected by probing with an antibody raised against NDUFB8 and
are in agreement with published studies.17 In (B) and (C), SDHA (Complex II) was used as loading control.
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screening was performed, revealing Wolff–Parkinson–White
(WPW) syndrome in patient 8, a rare cardiac conduction defect
which is over-represented in patients with mitochondrial disease.23
The initial manifestation of WPW syndrome can be sudden death
and the diagnosis might facilitate interventions including non-
invasive risk stratiﬁcation and/or therapeutic ablation.24
Many cases of isolated Complex I deﬁciency associated with
nuclear gene mutations are discrete entities and no common
variant accounts for more than a few apparently unrelated
cases.25 We present 10 patients from 8 families who harbour the
same homozygous NDUFB3 variant and share a plethora of uni-
fying physical features, an unprecedented ﬁnding in association
with isolated Complex I deﬁciency. Recognition of the distinct-
ive facial features in combination with short stature should
suggest screening for the c.64T>C, p.Trp22Arg NDUFB3 muta-
tion, even in the absence of ‘classic’ metabolic symptoms, and
particularly when Irish ancestry is involved.
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